ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
0.00%
US Dollar vs MXN
16.9351
-0.29%
Brent Oil
83.575
0.54%
Bitcoin
64,125.67
0.20%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. USOTC
  6. Revive Therapeutics Ltd (QB) (RVVTF)

  7. Revive Therapeutics Ltd (QB) (RVVTF) Noticias

RVVTF

Revive Therapeutics (QB) (RVVTF)

Revive Therapeutics Ltd (QB)
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:USOTC:RVVTF
FechaHoraFuenteTítuloSímboloCompañía
18/04/202209:26InvestorsHub NewsWireRevive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19USOTC:RVVTFRevive Therapeutics Ltd (QB)
12/04/202207:00InvestorsHub NewsWireRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19USOTC:RVVTFRevive Therapeutics Ltd (QB)
24/02/202207:35InvestorsHub NewsWireHAVN Life Secures Purchase Order for Controlled Substance Sale to Revive Therapeutics Ltd. for Use in Clinical ResearchUSOTC:RVVTFRevive Therapeutics Ltd (QB)
16/02/202207:03InvestorsHub NewsWireRevive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver TransplantationUSOTC:RVVTFRevive Therapeutics Ltd (QB)
17/01/202208:13InvestorsHub NewsWireRevive Therapeutics Provides Update of Psilocybin Pharmaceutical ProgramsUSOTC:RVVTFRevive Therapeutics Ltd (QB)
07/01/202207:05InvestorsHub NewsWireRevive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19USOTC:RVVTFRevive Therapeutics Ltd (QB)
16/11/202107:00InvestorsHub NewsWireRevive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection Delta VariantUSOTC:RVVTFRevive Therapeutics Ltd (QB)
22/09/202106:30InvestorsHub NewsWireRevive Therapeutics Included in AdvisorShares® Newly Launched Psychedelics ETFUSOTC:RVVTFRevive Therapeutics Ltd (QB)
18/08/202105:00InvestorsHub NewsWireRevive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat CancerUSOTC:RVVTFRevive Therapeutics Ltd (QB)
12/08/202108:56InvestorsHub NewsWireRevive Confirms No Material Undisclosed InformationUSOTC:RVVTFRevive Therapeutics Ltd (QB)
10/08/202107:52InvestorsHub NewsWireRevive Therapeutics Provides Update on Psychedelics Clinical Product PipelineUSOTC:RVVTFRevive Therapeutics Ltd (QB)
15/07/202113:47InvestorsHub NewsWireRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trialfor Bucillamine in COVID-19USOTC:RVVTFRevive Therapeutics Ltd (QB)
28/06/202107:00InvestorsHub NewsWireRevive Therapeutics Approved to Trade on the OTCQB MarketUSOTC:RVVTFRevive Therapeutics Ltd (QB)
17/06/202107:59InvestorsHub NewsWireRevive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of PsychedelicsUSOTC:RVVTFRevive Therapeutics Ltd (QB)
08/06/202108:12InvestorsHub NewsWireRevive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in IndiaUSOTC:RVVTFRevive Therapeutics Ltd (QB)
17/05/202108:48InvestorsHub NewsWireRevive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film StripUSOTC:RVVTFRevive Therapeutics Ltd (QB)
03/05/202108:32InvestorsHub NewsWireRevive Therapeutics Enters Into Research Agreement with UCSF For Bucillamine As Potential Treatment For Severe COVID-19USOTC:RVVTFRevive Therapeutics Ltd (QB)
27/04/202108:51InvestorsHub NewsWireRevive Therapeutics Files For FDA Orphan Drug Designation for Psilocybin in Traumatic Brain InjuryUSOTC:RVVTFRevive Therapeutics Ltd (QB)
22/04/202107:26InvestorsHub NewsWireRevive Therapeutics Announces Successful Research Results for Oral Thin Film Psilocybin and Filing of U.S. Provisional ....contUSOTC:RVVTFRevive Therapeutics Ltd (QB)
24/03/202108:15InvestorsHub NewsWireRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19USOTC:RVVTFRevive Therapeutics Ltd (QB)
19/03/202106:56InvestorsHub NewsWireRevive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of ...ContUSOTC:RVVTFRevive Therapeutics Ltd (QB)
26/02/202108:01InvestorsHub NewsWireRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion...ContUSOTC:RVVTFRevive Therapeutics Ltd (QB)
17/02/202108:53InvestorsHub NewsWireRevive Therapeutics Acquires Unique Psilocybin AssetsUSOTC:RVVTFRevive Therapeutics Ltd (QB)
11/02/202107:05InvestorsHub NewsWireRevive Therapeutics Provides Update on Cannabinoid Pharmaceuticals ProgramUSOTC:RVVTFRevive Therapeutics Ltd (QB)
27/01/202107:13InvestorsHub NewsWireRevive Therapeutics in Phase 3 clinical trial for COVID-19 treatmentUSOTC:RVVTFRevive Therapeutics Ltd (QB)
18/01/202108:51InvestorsHub NewsWireHow Combat Sports Are Researching Micro-Dosing Psychedelics To Treat Brain InjuriesUSOTC:RVVTFRevive Therapeutics Ltd (QB)
14/01/202107:30InvestorsHub NewsWireRevive Therapeutics Announces Research Collaboration with North Carolina State UniversityUSOTC:RVVTFRevive Therapeutics Ltd (QB)
31/12/202007:30InvestorsHub NewsWireDr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 StudyUSOTC:RVVTFRevive Therapeutics Ltd (QB)
23/12/202008:57InvestorsHub NewsWireRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for BucillamineUSOTC:RVVTFRevive Therapeutics Ltd (QB)
22/12/202010:05InvestorsHub NewsWireRevive Therapeutics Announces LOI to Acquire PharmaTher's Psilocybin ProgramUSOTC:RVVTFRevive Therapeutics Ltd (QB)
 Showing the most relevant articles for your search:USOTC:RVVTF

Su Consulta Reciente

NYSE
BAC
Bank of America
USOTC
BASFY
BASF (QX)
NASDAQ
MSFT
Microsoft
NASDAQ
GOOGL
Alphabet
USOTC
BNPQY
BNP Paribas (QX)
FX
EURMXN
Euro vs MXN
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
AXP
American Express
USOTC
RHHBY
Roche (QX)
NYSE
MRK
Merck
CCOM
US30
US 30
FX
USDMXN
US Dollar vs MXN
NYSE
VZ
Verizon Communications
NYSE
KO
Coca Cola
AMEX
XLE
Energy Select Sector SPDR
AMEX
XLV
Health Care Select Sector
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados